Consensus Maravai LifeSciences Holdings, Inc.

Stocks

MRVI

US56600D1072

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 14:10:02 2026-11-11 EST			5-day change	1st Jan Change
7.850 ^USD	-0.13%		+2.07%	+142.46%

11-07	Maravai LifeSciences Holdings, Inc., Q3 2026 Earnings Call, Nov 04, 2026
11-04	Earnings Flash (MRVI) Maravai LifeSciences Holdings, Inc. Reports Q3 Revenue $45.9M, vs. FactSet Est of $43.6M	MT

Evolution of the Average Target: Maravai LifeSciences Holdings, Inc.

Evolution of the Target Price: Maravai LifeSciences Holdings, Inc.

Changes in Analyst Recommendations: Maravai LifeSciences Holdings, Inc.

5830fe02e.aBlWZlkm60Qx1guxG4rWlN4W9--8bvFequTNlNyOaCA.BEBhVTVUoXJZomT1U_Ok0Id0nZfvI74IzICdxo_YDBNFKxgoPh_TGwKHZA~9ec5735994370bb8e73a6648f8c9cd32

Analysts' recommendations: Maravai LifeSciences Holdings, Inc.

10-05	TD Cowen Initiates Maravai Lifesciences at Buy With $9 Price Target	MT
09-09	UBS Adjusts Maravai Lifesciences Price Target to $8 From $2.50, Maintains Neutral Rating	MT
08-07	Deutsche Bank Adjusts Maravai Lifesciences PT to $8 From $6, Maintains Buy Rating	MT
05-08	Deutsche Bank Adjusts Maravai Lifesciences Price Target to $6 From $4.50, Maintains Buy Rating	MT
25-08-12	RBC Capital Adjusts Price Target on Maravai Lifesciences to $5 From $7, Maintains Outperform Rating	MT
25-08-12	Deutsche Bank Adjusts Maravai Lifesciences Price Target to $4.50 From $5, Maintains Buy Rating	MT
25-08-11	Maravai Q2 adjusted EPS misses estimates	RE
25-03-21	UBS Cuts Price Target on Maravai Lifesciences to $2.50 From $8, Keeps Neutral Rating	MT
25-03-21	Deutsche Bank Adjusts Price Target on Maravai Lifesciences to $5 From $10, Keeps Buy Rating	MT
25-02-26	Baird Downgrades Maravai Lifesciences to Neutral From Outperform, Cuts Price Target to $3 From $9	MT
24-12-19	Guggenheim Initiates Coverage on Maravai Lifesciences With Neutral Rating	MT
24-12-09	RBC Lowers Price Target on Maravai Lifesciences Holdings to $11 From $13, Keeps Outperform Rating	MT
24-12-05	Goldman Sachs Downgrades Maravai Lifesciences to Sell From Neutral, Cuts Price Target to $4.25 From $7	MT
24-11-14	Wolfe Research Initiates Maravai Lifesciences at Perform	MT
24-11-08	UBS Adjusts Price Target on Maravai Lifesciences to $8 From $11, Maintains Neutral Rating	MT
24-11-08	RBC Capital Adjusts Price Target on Maravai Lifesciences to $13 From $17, Maintains Outperform Rating	MT
24-11-08	William Blair Downgrades Maravai Lifesciences to Market Perform	MT
24-09-13	RBC Raises Price Target on Maravai LifeSciences Holdings to $17 From $15, Keeps Outperform Rating	MT
24-08-28	Wells Fargo Initiates Maravai LifeSciences at Overweight With $10 Price Target	MT
24-08-13	Morgan Stanley Downgrades Maravai LifeSciences to Equalweight From Overweight, Adjusts Price Target to $10 From $11	MT
24-08-08	UBS Adjusts Maravai LifeSciences Holdings Price Target to $11 From $8.50, Maintains Neutral Rating	MT
24-07-09	Goldman Sachs Trims Price Target on Maravai LifeSciences to $7 From $8, Maintains Neutral Rating	MT
24-05-09	UBS Raises Price Target on Maravai LifeSciences to $8.50 From $6.50, Maintains Neutral Rating	MT
24-05-09	Baird Adjusts Price Target on Maravai LifeSciences to $10 From $8, Keeps Outperform Rating	MT
24-04-10	Craig-Hallum Initiates Coverage on Maravai LifeSciences With Buy Rating, $15 Price Target	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MARAVAI LIFESCIENCES HOLDINGS, INC.					+19.8%
	WUXI APPTEC CO., LTD.					+34.62%
	ARGENX SE					+16.21%
	LONZA GROUP AG					+8.35%
	BEONE MEDICINES AG					+9.01%
	IQVIA HOLDINGS INC.					+13.35%
	REVOLUTION MEDICINES, INC.					+42.36%
	CELLTRION, INC.					+35.65%
	GENMAB A/S					+13.29%
	WUXI BIOLOGICS (CAYMAN) INC.					+21.4%
	Average					+21.40%
	Weighted average by Cap.					+21.37%